# Neurodegenerative disease therapeutic research

> Live situation record from CLSTR: https://clstr.news/situations/neurodegenerative-disease-therapeutic-research
> Updated: 2026-08-14T15:23:10.000Z. Sources: 4. Developments: 2.

Recent research has identified potential therapeutic pathways for treating neurodegenerative disorders by targeting protein accumulation in the brain.

In July 2026, researchers at the University of Denver introduced a synthetic molecule called SK-129. This foldamer binds to the protein alpha-synuclein, preventing the formation of toxic protein clumps associated with Parkinson’s disease. While mouse studies showed a reduction in disease-related symptoms, human testing and long-term safety assessments are still required.

By August 2026, a collaborative study between Swedish and American institutions reported progress in addressing Alzheimer’s disease. Using a synthetic gamma-secretase modulator known as AZ4126, researchers demonstrated in mouse models that the compound could reduce the formation of beta-amyloid plaques and potentially facilitate the regression of existing plaques.

## Timeline

### 2026-08-14: Alzheimer's research shows potential in reducing amyloid plaques

Researchers from Sweden and the US have found that the synthetic modulator AZ4126 can reduce and potentially regress beta-amyloid plaques in Alzheimer's disease mouse models.

4 sources. https://clstr.news/cluster/alzheimers-research-shows-potential-in-reducing-amyloid-plaques

### 2026-07-31: Synthetic foldamer SK-129 shows promise against Parkinson's disease

University of Denver scientists developed foldamer SK-129, which blocks alpha‑synuclein clumping and eases Parkinson’s symptoms in mice; human testing and safety remain pending.

3 sources. https://clstr.news/cluster/synthetic-foldamer-sk-129-shows-promise-against-parkinsons-disease

---
Cite as: Neurodegenerative disease therapeutic research. CLSTR, https://clstr.news/situations/neurodegenerative-disease-therapeutic-research